New AI Tool Illuminates "Dark Side" of the Human Genome

Proteins sustain life as we know it, serving many important structural and functional roles throughout the body. But these large molecules have cast a long shadow over a smaller subclass of proteins called microproteins. Microproteins have been lost in the 99% of DNA disregarded as "noncoding" - hiding in vast, dark stretches of unexplored genetic code. But despite being small and elusive, their impact may be just as big as larger proteins.

Salk Institute scientists are now exploring the mysterious dark side of the genome in search of microproteins. With their new tool ShortStop, researchers can probe genetic databases and identify DNA stretches in the genome that likely code for microproteins. Importantly, ShortStop also predicts which microproteins are most likely to be biologically relevant, saving time and money in the search for microproteins involved in health and disease.

ShortStop shines a new light on existing datasets, spotlighting microproteins formerly impossible to find. In fact, the Salk team has already used the tool to analyze a lung cancer dataset to find 210 entirely new microprotein candidates - with one standout validated microprotein - that may make good therapeutic targets in the future.

The findings were published in BMC Methods on July 31, 2025.

"Most of the proteins in our body are well known, but recent discoveries suggest we’ve been missing thousands of small, hidden proteins - called microproteins - coded by overlooked regions of our genome," says senior author Alan Saghatelian, professor and holder of the Dr. Frederik Paulsen Chair at Salk. "For a long time, scientists only really studied the regions of DNA that coded for large proteins and dismissed the rest as ‘junk DNA,’ but we’re now learning that these other regions are actually very important, and the microproteins they produce could play critical roles in regulating health and disease."

It is difficult to detect and catalog microproteins, owing mostly to their size. Compared to standard proteins that can range from hundreds to thousands of amino acids long, microproteins typically contain fewer than 150 amino acids, making them harder to detect using standard protein analysis methods. Therefore, instead of searching for the microproteins themselves, scientists search large, publicly available datasets for the DNA sequences that make them.

Scientists have now learned that certain stretches of DNA called small open reading frames (smORFs) can contain the instructions for making microproteins. Current experimental methods have already cataloged thousands of smORFs, but these tools remain time-consuming and expensive. Furthermore, their inability to separate potentially functional microproteins from nonfunctional microproteins has stalled their discovery and characterization.

Not all smORFs translate to biologically meaningful microproteins. Existing methods can’t discriminate between functional and nonfunctional microprotein-generating smORFs. This means that scientists must independently test each microprotein to determine whether it is functional or not.

ShortStop radically alters this workflow, optimizing smORF discovery by sorting microproteins into functional and nonfunctional categories. The key to ShortStop’s two-class sorting is how it’s trained as a machine learning system. Its training relies on a negative control dataset of computer-generated random smORFs. ShortStop compares found smORFs against these decoys to quickly decide whether a new smORF is likely to be functional or nonfunctional.

ShortStop cannot definitively say whether a smORF will code for a biologically relevant microprotein, but this two-class system narrows down the experimental pool immensely. Now researchers can spend less time manually sorting through datasets and failing at the bench.

When the researchers applied ShortStop to a previously published smORF dataset, they identified 8% as likely functional microproteins, prioritizing them for targeted follow-up. This accelerates microprotein characterization by filtering out sequences unlikely to have biological relevance. ShortStop could also identify microproteins that were overlooked by other methods, including one that was validated by being detected in human cells and tissues.

"What makes ShortStop especially powerful is that it works with common data types, like RNA sequencing datasets, which many labs already use," says first author Brendan Miller, a postdoctoral researcher in Saghatelian’s lab. "This means we can now search for microproteins across healthy and diseased tissues at scale, which will reveal new insights into human biology and unlock new paths for diagnosing and treating diseases, such as cancer and Alzheimer’s disease."

The researchers have already used ShortStop to identify a microprotein that was upregulated in lung cancer tumors. They analyzed genetic data from human lung tumors and adjacent normal tissue to create a list of potential functional smORFs. Among the smORFs ShortStop found, one stood out - it was expressed more in tumor tissue than normal tissue, suggesting it may serve as a biomarker or functional microprotein for lung cancer

The identification of this lung cancer-related microprotein demonstrates the value of ShortStop and machine learning to prioritize candidates for future research and therapeutic development.

"There’s so much data that already exists that we can now process with ShortStop to find novel microproteins associated with health and disease, stretching from Alzheimer’s to obesity and beyond," says Saghatelian. "My team is really good at making methods, and with data from other Salk faculty, we can integrate these methods and accelerate the science."

Miller B, de Souza EV, Pai VJ, Kim H, Vaughan JM, Lau CJ, Diedrich JK, Saghatelian A.
ShortStop: a machine learning framework for microprotein discovery.
BMC Methods. 2025;2(1):16. doi: 10.1186/s44330-025-00037-4

Most Popular Now

AI-Powered CRISPR could Lead to Faster G…

Stanford Medicine researchers have developed an artificial intelligence (AI) tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help...

Groundbreaking AI Aims to Speed Lifesavi…

To solve a problem, we have to see it clearly. Whether it’s an infection by a novel virus or memory-stealing plaques forming in the brains of Alzheimer’s patients, visualizing disease processes...

AI Spots Hidden Signs of Depression in S…

Depression is one of the most common mental health challenges, but its early signs are often overlooked. It is often linked to reduced facial expressivity. However, whether mild depression or...

AI Tools Help Predict Severe Asthma Risk…

Mayo Clinic researchers have developed artificial intelligence (AI) tools that help identify which children with asthma face the highest risk of serious asthma exacerbation and acute respiratory infections. The study...

AI Model Forecasts Disease Risk Decades …

Imagine a future where your medical history could help predict what health conditions you might face in the next two decades. Researchers have developed a generative AI model that uses...

AI Model Indicates Four out of Ten Breas…

A project at Lund University in Sweden has trained an AI model to identify breast cancer patients who could be spared from axillary surgery. The model analyses previously unutilised information...

ChatGPT 4o Therapeutic Chatbot 'Ama…

One of the first randomized controlled trials assessing the effectiveness of a large language model (LLM) chatbot 'Amanda' for relationship support shows that a single session of chatbot therapy...

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

Smart Device Uses AI and Bioelectronics …

As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called "a-Heal," designed by engineers at the University...

Overcoming the AI Applicability Crisis a…

Opinion Article by Harry Lykostratis, Chief Executive, Open Medical. The government’s 10 Year Health Plan makes a lot of the potential of AI-software to support clinical decision making, improve productivity, and...

Dartford and Gravesham Implements Clinis…

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering using Clinisys ICE. The trust deployed the order communications...